

## PE anti-mouse CD62L Antibody

<b>Catalog# / Size</b>	104407 / 50 µg 104408 / 200 µg
<b>Clone</b>	MEL-14
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	C3H/eb mouse B lymphoma 38C-13
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10 <sup>6</sup> cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunoprecipitation <sup>1-3</sup> , complement-dependent cytotoxicity <sup>4</sup> , <i>in vivo</i> and <i>in vitro</i> blocking of adhesion <sup>1-3,5</sup> , and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections <sup>6</sup> . The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).
<b>Application References</b>	<ol style="list-style-type: none"> <li>Gallatin WM, <i>et al.</i> 1983. <i>Nature</i> 304:30. (IP, Block)</li> <li>Siegelman MH, <i>et al.</i> 1990. <i>Cell</i> 61:611. (IP, Block)</li> <li>Lewinsohn DM, <i>et al.</i> 1987. <i>J. Immunol.</i> 138:4313. (IP, Block)</li> <li>Iwabuchi K, <i>et al.</i> 1991. <i>Immunobiology</i> 182:161. (CMCD)</li> <li>Pizcueta P, <i>et al.</i> 1994. <i>Am. J. Pathol.</i> 145:461.</li> <li>Reichert RA, <i>et al.</i> 1986. <i>J. Immunol.</i> 136:3535. (IHC, FC)</li> <li>Olver S, <i>et al.</i> 2006. <i>Cancer Res.</i> 66:571.</li> <li>Fukushima A, <i>et al.</i> 2006. <i>Invest. Ophthalmol. Vis. Sci.</i> 47:657. <a href="#">PubMed</a></li> </ol>

9. Benson MJ, *et al.* 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
10. Chappaz S, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-074245. (FC) [PubMed](#)
11. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181.
12. Shigeta A, *et al.* 2008. *Blood* 112:4915 (FC) [PubMed](#)
13. de Vries VC, *et al.* 2009. *Am. J. Transplant.* 9:2270 [PubMed](#)

## Product Citations

1. Chen N, *et al.* 2021. *Front Immunol.* 12:756423. [PubMed](#)
2. Pani F, *et al.* 2021. *Endocrinology.* 162:. [PubMed](#)
3. Laura C Burzynski *et al.* 2019. *Immunity.* 50(4):1033-1042 . [PubMed](#)
4. Dong MB, *et al.* 2020. *Cell.* 178(5):1189-1204.e23.. [PubMed](#)
5. Li B, Schmidt N 2016. *PLoS One.* 11: 0162427. [PubMed](#)
6. Soon MSF, *et al.* 2020. *Nat Immunol.* 1.984027778. [PubMed](#)
7. Song Y, *et al.* 2020. *Front Immunol.* 11:558143. [PubMed](#)
8. Yu Y, *et al.* 2022. *iScience.* 25:105004. [PubMed](#)
9. Van Den Eeckhout B, *et al.* 2020. *NPJ Vaccines.* 5:64. [PubMed](#)
10. Yang C, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
11. Hewitson JP, *et al.* 2020. *J Immunol.* 204:2949. [PubMed](#)
12. Duan Q, *et al.* 2021. *Front Cell Dev Biol.* 9:761193. [PubMed](#)
13. Sawada J, *et al.* 2021. *Am J Pathol.* 191:396. [PubMed](#)
14. Ren S, *et al.* 2019. *Oncol Rep.* 41:1509. [PubMed](#)
15. Liu QZ, *et al.* 2018. *Front Immunol.* 1.131944444. [PubMed](#)
16. MacDonald K, *et al.* 2014. *J Immunol.* 192:3180. [PubMed](#)
17. Zhao J, *et al.* 2019. *Nat Commun.* 10:899. [PubMed](#)
18. Hamasato E, *et al.* 2014. *Brain Behav Immun.* 11:109. [PubMed](#)
19. Garcia Nores GD, *et al.* 2018. *Nat Commun.* 9:1970. [PubMed](#)
20. Misumi I *et al.* 2019. *Cell Rep.* 27(2):514-524 . [PubMed](#)
21. Bartleson JM, *et al.* 2020. *Nat Immunol.* 1384:21. [PubMed](#)
22. Ontiveros-Padilla L, *et al.* 2021. *Microorganisms.* 9:. [PubMed](#)
23. Stewart JM, *et al.* 2020. *ACS Biomater Sci Eng.* 6:5941. [PubMed](#)
24. Hojo MA, *et al.* 2019. *Nat Commun.* 2.224305556. [PubMed](#)
25. Hiramoto T, *et al.* 2018. *Mol Ther.* 26:1255. [PubMed](#)
26. Imani J, *et al.* 2021. *JCI Insight.* 6:. [PubMed](#)
27. Wang J, *et al.* 2021. *Nat Commun.* 12:6198. [PubMed](#)
28. Lu X, *et al.* 2020. *Sci Transl Med.* 12:. [PubMed](#)
29. Akazawa S, *et al.* 2021. *Diabetologia.* 64:878. [PubMed](#)
30. Ng SS, *et al.* 2020. *Nat Immunol.* 21:1205. [PubMed](#)
31. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
32. Green WD, *et al.* 2022. *J Leukoc Biol.* 111:147. [PubMed](#)
33. Coquery C, *et al.* 2014. *PLoS One.* 9:102284. [PubMed](#)
34. Lu X, *et al.* 2015. *J Immunol.* 194:2011. [PubMed](#)
35. Trefzer A, *et al.* 2021. *Cell Reports.* 34(6):108748. [PubMed](#)
36. Frost JN, *et al.* 2021. *Med (N Y).* 2:164. [PubMed](#)
37. Kyburz A, *et al.* 2019. *J Allergy Clin Immunol.* 143:1496. [PubMed](#)
38. Sendler M, *et al.* 2020. *Gastroenterology.* 158:253. [PubMed](#)
39. Simula L *et al.* 2018. *Cell reports.* 25(11):3059-3073 . [PubMed](#)
40. Zhu X *et al.* 2019. *Cell reports.* 27(4):1205-1220 . [PubMed](#)
41. Li D, *et al.* 2022. *Emerg Microbes Infect.* 11:2248. [PubMed](#)
42. Yang BH, *et al.* 2020. *Cell Reports.* 27(12):3629-3645.e6.. [PubMed](#)
43. Kretschmer L, *et al.* 2020. *Nat Commun.* 0.536805556. [PubMed](#)
44. Ma X, *et al.* 2020. *Immunity.* 53:1315. [PubMed](#)
45. Wei Z, *et al.* 2021. *Nat Commun.* 0.805555556. [PubMed](#)
46. Robertson TF, *et al.* 2021. *J Cell Biol.* 220:. [PubMed](#)
47. Gladow N, *et al.* 2020. *PLoS One.* 15:e0227734. [PubMed](#)
48. Zheng B, *et al.* 2021. *Bioact Mater.* 6:3879. [PubMed](#)
49. Li M, *et al.* 2021. *Br J Pharmacol.* 178:2617. [PubMed](#)
50. Oliveira AC *et al.* 2017. *eLife.* 6 pii: e30883. [PubMed](#)
51. Fernández-Orth J, *et al.* 2020. *Eur J Immunol.* . [PubMed](#)
52. Chao JL, *et al.* 2021. *Cell Rep Med.* 2:100399. [PubMed](#)
53. Sun Y, *et al.* 2020. *J Immunol.* 205:2649. [PubMed](#)
54. Rui J, *et al.* 2021. *Nat Commun.* 12:5074. [PubMed](#)
55. Xu Y, *et al.* 2021. *iScience.* 24:103445. [PubMed](#)
56. Van Den Eeckhout B, *et al.* 2020. *NPJ Vaccines.* 0.252777778. [PubMed](#)
57. Ramanan D, *et al.* 2020. *Cell.* 181(6):1276-1290. [PubMed](#)
58. Lee MC, *et al.* 2017. *J Immunol.* 198:3565. [PubMed](#)
59. Lu Y, *et al.* 2018. *Cancer Cell.* 33:1048. [PubMed](#)
60. Charlton J, *et al.* 2015. *PLoS One.* 10:119200. [PubMed](#)
61. Deptuch T, *et al.* 2022. *Sci Rep.* 12:13480. [PubMed](#)
62. Geng S, *et al.* 2019. *Sci Adv.* 5:eaav2309. [PubMed](#)
63. Bantug GR, *et al.* 2018. *Immunity.* 48:542. [PubMed](#)
64. Angela M, *et al.* 2016. *Nat Commun.* 7:13683. [PubMed](#)
65. Corrado M, *et al.* 2020. *Cell Metab.* 32:981. [PubMed](#)
66. Tian T, *et al.* 2020. *Cancer Immunol Res.* 660:8. [PubMed](#)
67. Cao Y, *et al.* 2022. *Small.* 18:e2203466. [PubMed](#)
68. Liu Y, *et al.* 2021. *Nat Commun.* 12:6831. [PubMed](#)
69. Guo S, *et al.* 2021. *Frontiers in Immunology.* 11:614667. [PubMed](#)
70. Olguin J, *et al.* 2015. *Microbes Infect.* 17: 586-595. [PubMed](#)

## Antigen Details

<b>Structure</b>	Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
<b>Distribution</b>	Subsets of B and T cells, monocytes, granulocytes, subset of NK cells
<b>Function</b>	Lymphocyte homing to HEV, rolling on activated endothelium
<b>Ligand/Receptor</b>	CD34, GlyCAM-1, MAdCAM-1
<b>Cell Type</b>	B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
<b>Biology Area</b>	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
<b>Molecular Family</b>	Adhesion Molecules, CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay AN, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.</li> <li>2. Kishimoto TK, <i>et al.</i> 1990. <i>P. Natl. Acad. Sci. USA</i> 87:2244.</li> <li>3. Tedder TF, <i>et al.</i> 1995. <i>J. Exp. Med.</i> 181:2259.</li> </ol>
<b>Gene ID</b>	<a href="#">20343</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD62L, Biotin anti-mouse CD62L, FITC anti-mouse CD62L, PE anti-mouse CD62L, PE/Cyanine5 anti-mouse CD62L, Purified anti-mouse CD62L, PE/Cyanine7 anti-mouse CD62L, Alexa Fluor® 488 anti-mouse CD62L, Alexa Fluor® 647 anti-mouse CD62L, Pacific Blue™ anti-mouse CD62L, Alexa Fluor® 700 anti-mouse CD62L, APC/Cyanine7 anti-mouse CD62L, PerCP/Cyanine5.5 anti-mouse CD62L, PerCP anti-mouse CD62L, Brilliant Violet 421™ anti-mouse CD62L, Brilliant Violet 570™ anti-mouse CD62L, Brilliant Violet 605™ anti-mouse CD62L, Brilliant Violet 510™ anti-mouse CD62L, Purified anti-mouse CD62L (Maxpar® Ready), Brilliant Violet 711™ anti-mouse CD62L, Brilliant Violet 785™ anti-mouse CD62L, PE/Dazzle™ 594 anti-mouse CD62L, APC/Fire™ 750 anti-mouse CD62L, TotalSeq™-A0112 anti-mouse CD62L, Brilliant Violet 650™ anti-mouse CD62L, TotalSeq™-C0112 anti-mouse CD62L, Ultra-LEAF™ Purified anti-mouse CD62L, KIRAVIA Blue 520™ anti-mouse CD62L, TotalSeq™-B0112 anti-mouse CD62L

## Product Data



C57BL/6 mouse splenocytes stained with MEL-14 PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587